US-based biopharma Silver Creek Pharmaceuticals’ late intervention acute ischemic stroke candidate, SCP-776, has demonstrated varied results in a mid-stage trial. During the Phase II ARPEGGIO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback